Literature DB >> 8700118

Bimodal distribution of renal cytochrome P450 3A activity in humans.

B D Haehner1, J C Gorski, M Vandenbranden, S A Wrighton, S K Janardan, P B Watkins, S D Hall.   

Abstract

It has been proposed that excessive intrarenal conversion of cortisol to 6 beta-hydroxycortisol by CYP3A may mediate increased tubular reabsorption of sodium, leading to a state of mild volume expansion and the clinical phenotype of salt-sensitive hypertension. Therefore, we characterized CYP3A activity in a bank of microsomes from human kidneys using the formation of 1'-hydroxymidazolam (1'-OHM) as a prototypical CYP3A-catalyzed reaction. Maximal rates of metabolite formation occurred at midazolam concentrations of 12.5-50 microM; higher concentrations resulted in dramatic substrate inhibition. At 12.5 microM midazolam, 4 of 27 kidneys exhibited relatively high mean +/- standard deviation 1'-OHM formation rate (184.0 +/- 14.4 pmol/hr/mg) compared with the remaining 23 samples, which had a mean formation rate of (10.1 +/- 6.4 pmol/hr/mg). Triacetyloleandomycin and anti-CYP3A antibody inhibited midazolam hydroxylation by 53% and 57%, respectively. The correlation between CYP3A5 content, determined through immunoblotting, and 1'-OHM formation rate was high (r2 = 0.84, 24 experiments). The expressions of mRNA corresponding to CYP3A3, CYP3A4, CYP3A5, and CYP3A7 were determined through polymerase chain reaction with specific oligonucleotides as primers. All kidneys examined (25 experiments) expressed CYP3A5 protein and contained the corresponding CYP3A5 mRNA. CYP3A4 mRNA was detected in 40% of the kidney samples, and 70% of those that contained detectable CYP3A4 mRNA also expressed detectable levels of the corresponding protein. Therefore, in contrast to hepatic tissue, in which CYP3A4 is universally expressed, CYP3A5 is the ubiquitously expressed member of the CYP3A family in renal tissue. The distribution of enzyme activity and protein content suggests bimodality and may represent induction of CYP3A5 in a select population and/or a genetically determined organ-specific pattern of expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700118

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  36 in total

1.  The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

Authors:  Donna J Belle; John T Callaghan; J Christopher Gorski; Juan F Maya; Omiema Mousa; Steven A Wrighton; Stephen D Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 2.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

3.  Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.

Authors:  J-B Woillard; J-P Rerolle; N Picard; A Rousseau; A Guillaudeau; E Munteanu; M Essig; M Drouet; Y Le Meur; P Marquet
Journal:  Clin Pharmacol Ther       Date:  2010-05-26       Impact factor: 6.875

4.  CYP3A phenotypes and genotypes in North Indians.

Authors:  Naushad Rais; Yogesh K Chawla; Krishan K Kohli
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

Review 5.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

6.  A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system.

Authors:  Su-Jun Lee; Ilse P van der Heiden; Joyce A Goldstein; Ron H N van Schaik
Journal:  Drug Metab Dispos       Date:  2006-10-11       Impact factor: 3.922

Review 7.  The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.

Authors:  Y Zhang; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 8.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

9.  Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells.

Authors:  Lawrence H Lash; David A Putt; Hongliang Cai
Journal:  Toxicology       Date:  2007-11-04       Impact factor: 4.221

10.  The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates.

Authors:  Oliver Burk; Matthias Schwab
Journal:  Eur J Clin Pharmacol       Date:  2007-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.